今年前三月中国创新药对外授权超600亿美元，逼近去年全年一半

Core Viewpoint - The article highlights the significant growth and international recognition of China's innovative pharmaceuticals, with a total authorization amount exceeding $60 billion in the first quarter of 2026, indicating a strong development trend during the 14th Five-Year Plan period [3]. Group 1: Innovative Drug Authorization - In the first quarter of 2026, China's innovative drug authorization total exceeded $60 billion, approaching half of the total for the entire year of 2025, which was a record $130 billion [3]. - In 2025, China approved a record 76 innovative drugs, marking a historical high for the country [3]. - As of March 27, 2026, the National Medical Products Administration (NMPA) approved 10 new drugs, with 8 being original innovations from China [3]. Group 2: Regulatory Framework Enhancements - The NMPA plans to enhance the policy framework to encourage, protect, and serve innovation, focusing on four key areas [4]. - A comprehensive revision of the Drug Administration Law will take effect on May 15, 2026, with over 90% of its provisions being updated to reflect recent regulatory reforms [4]. - The revised law aims to accelerate drug registration processes for pediatric and rare disease treatments, providing market exclusivity and data protection for innovative drugs [4]. Group 3: Safety and Quality Assurance - In 2025, the NMPA handled over 105,800 cases to eliminate safety risks, maintaining a drug inspection pass rate of over 99% [5]. - The NMPA will enhance regulatory collaboration across regions and levels, utilizing digital and intelligent methods to improve the efficiency of drug regulation [5]. Group 4: Scientific and Technical Support - The NMPA emphasizes the implementation of a regulatory science action plan, focusing on cutting-edge fields such as cell and gene therapy, AI drug development, and brain-machine interfaces [6]. - The agency aims to align China's drug registration technical requirements with international standards and participate in global regulatory coordination [7]. Group 5: Capacity Building and Local Initiatives - The NMPA is committed to building professional technical teams to enhance the precision and scientific level of drug regulation in key areas [8]. - Regional centers have been established to support drug and medical device review processes, with Beijing leading in the approval of innovative drugs and high-end medical devices [9].